Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
BURLINGTON, Mass., Dec. 04, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 9:45 a.m. Eastern Time at the Westin Grand Central Hotel in New York City.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of local, injectable, non-opioid drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead product candidate, Zilretta™, has been designed to provide improved analgesic therapy for the five million patients who receive intra-articular (IA) injections for osteoarthritis (OA) of the knee annually. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an IA, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.
CONTACTS: Investor Relations Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Relations Contact Mariann Caprino TogoRun 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
